SEEDSUPPLY advances early-stage drug discovery through experimental binding technologies, large-scale compound screening, and systematic studies of challenging drug targets.
Our research focuses on generating experimental binding data, discovering new chemical starting points, and evaluating the applicability of AI-based approaches to drug discovery.
SLAS Discovery (2026)
Binder2030 provides experimentally validated small-molecule binders for approximately 400 membrane protein targets, including GPCRs, SLC transporters, and ion channels.
Our scientific webinars explore the challenges and opportunities of experimental drug discovery, including AI-based virtual screening, small-molecule hit discovery, and target identification.
New webinars will be announced following the publication of our latest research.